Crititech, Inc.

Aranza Barreda Abarca

Michael Baltezor

Joseph S Farthing

Mark D Williams

Jacob M Sittenauer

Shelby Clark

Gere Dizerega

The disclosure provides particles of at least 95% by weight of lapatinib, or a pharmaceutically acceptable salt thereof, wherein the particles have a specific surface area (SSA) of at least 10 m/g and have a mean particle size by volume distribution of between about 0.7 μm and about 8 μm.

Lapatinib particles and uses thereof

Compositions of particles having at least 95% by weight of niraparib and a specific surface area (SSA) of at least 5 m/g, methods for their use, and methods for their production are provided.

Niraparib particles and uses thereof

Compositions of particles having at least 95% by weight of rucaparib and a specific surface area (SSA) of at least 12 m/g, methods for their use, and methods for their production are provided.

Growing community of inventors

Lawrence, KS, United States of America

Aranza Barreda Abarca